The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells

We formerly demonstrated that vaccination with Wilms' tumor 1 (WT1)-loaded autologous monocyte-derived dendritic cells (mo-DCs) can be a well-tolerated effective treatment in acute myeloid leukemia (AML) patients. Here, we investigated whether we could introduce the receptor for hyaluronic acid...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-11, Vol.7 (45), p.73960-73970
Main Authors: Willemen, Yannick, Van den Bergh, Johan M J, Bonte, Sarah M, Anguille, Sébastien, Heirman, Carlo, Stein, Barbara M H, Goossens, Herman, Kerre, Tessa, Thielemans, Kris, Peeters, Marc, Van Tendeloo, Viggo F I, Smits, Evelien L J, Berneman, Zwi N
Format: Article
Language:English
Subjects:
Antigen Presentation - immunology
Antigens, Neoplasm - immunology
Cancer Vaccines - immunology
Dendritic Cells - immunology
Dendritic Cells - metabolism
Electroporation
Extracellular Matrix Proteins - genetics
Extracellular Matrix Proteins - immunology
Gene Expression
HLA-A Antigens - immunology
Humans
Hyaluronan Receptors - genetics
Hyaluronan Receptors - immunology
Immunotherapy
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - immunology
Leukemia, Myeloid, Acute - therapy
Neoplasms - genetics
Neoplasms - immunology
Neoplasms - metabolism
Neoplasms - therapy
Research Paper
RNA, Messenger - genetics
RNA, Messenger - metabolism
T-Lymphocytes - immunology
T-Lymphocytes - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We formerly demonstrated that vaccination with Wilms' tumor 1 (WT1)-loaded autologous monocyte-derived dendritic cells (mo-DCs) can be a well-tolerated effective treatment in acute myeloid leukemia (AML) patients. Here, we investigated whether we could introduce the receptor for hyaluronic acid-mediated motility (RHAMM/HMMR/CD168), another clinically relevant tumor-associated antigen, into these mo-DCs through mRNA electroporation and elicit RHAMM-specific immune responses. While RHAMM mRNA electroporation significantly increased RHAMM protein expression by mo-DCs, our data indicate that classical mo-DCs already express and present RHAMM at sufficient levels to activate RHAMM-specific T cells, regardless of electroporation. Moreover, we found that RHAMM-specific T cells are present at vaccination sites in AML patients. Our findings implicate that we and others who are using classical mo-DCs for cancer immunotherapy are already vaccinating against RHAMM.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.12170